EGFR and non-small cell lung carcinoma: However, small sample sizes may hurt the generalizability of certain models clinically.95–97 A study attempted to use a random forest-based classifier to predict mutation status in lung cancer patients with BM using contrast-enhanced T1-weighted and T2-FLAIR MRIs evaluating, EGFR, ALK, and KRAS mutation status.97 These studies show promise for radiomics as a tool for managing NSCLC patients exhibiting BM.